View ValuationGenus 향후 성장Future 기준 점검 0/6Genus 의 수익은 연간 2.7% 감소할 것으로 예상되는 반면, 연간 수익은 3.2% 로 증가할 것으로 예상됩니다. EPS는 연간 0.6% 만큼 쇠퇴할 것으로 예상됩니다. 자기자본이익률은 3년 후 10.4% 로 예상됩니다.핵심 정보-2.7%이익 성장률-0.62%EPS 성장률Biotechs 이익 성장25.2%매출 성장률3.2%향후 자기자본이익률10.36%애널리스트 커버리지Good마지막 업데이트11 May 2026최근 향후 성장 업데이트공시 • Feb 16Genus plc Provides Earnings Guidance for the First Half of Fiscal 2024Genus plc provided earnings guidance for the first half of fiscal 2024. For the first half period, management expects to report revenue of £334 Million.모든 업데이트 보기Recent updates공시 • Jan 24+ 1 more updateHealth Canada and CFIA Announce Completion of Safety Assessments on PRRSV-Resistant Pigs from Genus PLC and PIC Canada, LtdHealth Canada and the Canadian Food Inspection Agency (CFIA) announced the completion of independent, comprehensive safety assessments on pigs resistant to PRRSV following applications from Genus PLC and PIC Canada Ltd., respectively. Health Canada has concluded that foods made from these pigs are as safe and nutritious for people to eat as pork currently available in Canada. The CFIA has confirmed that these pigs are also safe and effective for use in livestock feeds. Improving resistance to PRRSV in pigs will help farmers avoid illness in their herds from these viruses, reduce antibiotic use, and improve animal welfare, while supporting a more stable, affordable and sustainable food supply. Genus PLC's PRRSV-resistant pigs are already permitted for food use in the U.S., Brazil, Colombia and the Dominican Republic. Genus PLC has indicated that even though Canada has approved the sale of PRRSV resistant pigs, the company does not intend to sell these pigs before further regulatory authorization in other key markets. The company and Health Canada are committed to the highest level of transparency and will communicate to the public when this new technology enters the Canadian market. While genetically engineered foods are considered as safe and nutritious as conventional foods, the Government of Canada recognizes that information about genetic engineering is important. That is why have been working with the Canadian General Standards Board since November on a public review of the National Standard for labelling and advertising of foods that are, and are not, products of genetic engineering. The CFIA uses this Standard to provide its guidance to companies on the labelling of foods.공시 • Jan 08Genus plc to Report Fiscal Year 2026 Results on Sep 10, 2026Genus plc announced that they will report fiscal year 2026 results on Sep 10, 2026공시 • Nov 21+ 1 more updateGenus plc Approves to Appoint Andrew Russell as A DirectorGenus plc announced that at its AGM held on 19 November 2025, the shareholder approved to elect Andrew Russell as a Director of the Company.공시 • Nov 20Genus plc Announces Board AppointmentsGenus plc announced the appointment of Dr Celia Baxter to the Board as a Non-Executive Director with effect from 19 November 2025, and the appointment of Dr Robert Reiter as a Non-Executive Director with effect from 1 January 2026. Dr Baxter has had extensive experience inpeople-driven, multisite, manufacturing, services and distribution businesses across business sectors in international FTSE 100 and FTSE 250 companies as well as Big Four consulting, having worked in increasingly senior Human Resources roles at Ford Motor Company, KPMG, Sherwood Computer Services, Tate & Lyle, Enterprise Oil plc, Hays and Bunzl where she was Group Human Resources Director. Dr Baxter has a PhD in Botany from Reading Universityandis currently a non-executive director and remuneration committee chair of Volution Group plc, senior independent director and remuneration committee chair of discoverIE Group plc, and senior independent director and remuneration committee chair of Dowlais Group plc. She was previously a non-executive director of Senior plc, RHI Magnesita NV and Bekaert SA. Dr Baxter brings widespread global experience in Human Resources, Strategy, Branding, Mergers and Acquisitions and Change Management. Dr Reiteris a plant geneticist by training and spent his executive career delivering innovative new technologies and products within crop agriculture, having worked in E.I. DuPont de Nemours, followed by twenty years in increasingly senior scientific and supply chain leadership roles at Monsanto. Bob was the R&D Integration Planning Lead for the Bayer-Monsanto merger, collaborating with Bayer to design a world-class agricultural R&D organisation, overseeing an annual investment portfolio exceeding $2.3 billion. Following the acquisition of Monsanto, Bob became an Executive Vice President leading Research & Development for the combined Bayer Crop Science division, and integrated the two divisions with accountability of over 7,000 employees.공시 • Nov 19Genus plc to Report First Half, 2026 Results on Feb 26, 2026Genus plc announced that they will report first half, 2026 results on Feb 26, 2026공시 • Oct 10Genus plc, Annual General Meeting, Nov 19, 2025Genus plc, Annual General Meeting, Nov 19, 2025. Location: buchanan communications, 107 cheapside, ec2v 6dn, london United Kingdom공시 • Sep 04Genus plc Proposes Final Dividend for the Year 2025, Payable on December 5, 2025Genus plc proposed a final dividend of 21.7 pence per share for 2025. This is subject to shareholders' approval at the AGM and we have therefore not included it as a liability in these Financial Statements. The total proposed and paid dividend for year ended 30 June 2025 is 32.0 pence per share (2024: 32.0 pence per share). It is proposed that the final dividend will be paid on 5 December 2025 to the shareholders on the register at the close of business on 7 November 2025.공시 • May 02Genus plc Announces the Update in Relation to Its Innovative Prrs 1 Resistant Pig ProgrammeGenus announced that the U.S. Food and Drug Administration ("FDA") has approved the PRP gene edit for use in the U.S. food supply chain, in line with expectations. This landmark approval follows years of close collaboration with the FDA and is a significant step on the pathway to PRP commercialisation in the U.S. Genus believes successful U.S. commercialisation also requires approvals in key U.S. export markets, being Mexico, Canada and Japan. The Group continues to make progress with regulators in these jurisdictions as well as with other international regulators, including China. Brazil, Colombia and, more recently, the Dominican Republic have already issued positive determinations for PRP, meaning those countries will regulate the PRP the same as any other pigs. PRRS is one of the most devastating global pig diseases and causes suffering and premature death for pigs. Recent research indicates that PRRS also increases the need for antibiotics by more than 200%.공시 • Mar 13+ 1 more updateGenus plc Appoints Andy Russell as Chief Financial Officer, Effective August 1, 2025The Board of Genus plc announced that it has appointed Andy Russell as Chief Financial Officer. Andy will commence with Genus and join the Board on 1 August 2025, taking over from Alison Henriksen after she retires from the Company on 31 July 2025, after more than five years in the role. Andy is an experienced CFO, who will join Genus after nearly 12 years with global medical device manufacturer Smith & Nephew plc. He currently serves as Senior Vice President, Group Finance and M&A, operating as deputy to the Group CFO and leading approximately 400 people globally as he oversaw Group reporting, Controllership, FP&A, Tax, Treasury and M&A. This follows a succession of increasingly senior roles within the organisation, including CFO for the Global Orthopedics division, Interim President for EMEA and CFO for EMEA (while also acting as Finance lead for Global M&A and Strategic Projects). Before joining Smith & Nephew, Andy spent 17 years with KPMG, the last three of them as a Director, Transaction Services in the National Markets Division and the Private Equity Group.공시 • Feb 26Genus plc Announces Retirement of Jason Chin as Non-Executive Director from the Board, Effective from the End of May 2025Genus plc announced that Professor Jason Chinhas informed the Company of his intention to step down from the Genus Board, effective from the end of May 2025, as he will be taking on a significant new role as Founding Director of the Generative Biology Institute at the Ellison Institute of Technology. Professor Chin has served as a Non-Executive Director, Chairman of the Company's Scientific Advisory Board and advisor to the Company's Global Portfolio Steering Committee for four years. Upon stepping down from the Board, Professor Chin will remain a member of the Scientific Advisory Board. The Board has initiated a comprehensive search for Professor Chin's successor and will provide an update once this process has concluded.공시 • Nov 30Genus plc to Report Fiscal Year 2025 Results on Sep 04, 2025Genus plc announced that they will report fiscal year 2025 results on Sep 04, 2025공시 • Nov 21Genus plc Declares A Final DividendGenus plc declared a final dividend of 21.7 pence per Ordinary Share, at its AGM held on 20 November 2024.공시 • Nov 20Genus plc to Report First Half, 2025 Results on Feb 27, 2025Genus plc announced that they will report first half, 2025 results on Feb 27, 2025공시 • Oct 22Genus plc Announces Retirement of Alison Henriksen as Chief Financial Officer, Until 31 July 2025Genus announced that Alison Henriksen, Chief Financial Officer, has informed the Board of her intention to retire after five years with the Group. Alison will remain in her existing role until 31 July 2025 to assist with the transition and continue to focus on delivery of the Group's strategic priorities until her retirement.공시 • Sep 05Genus plc Proposes Final Dividend for the Year Ended June 30, 2024, Payable on 6 December 2024Genus plc board proposed a final dividend of 21.7 pence per ordinary share, consistent with the prior year final dividend. Payable on, 6 December 2024 to the shareholders on the register at the close of business on 8 November 2024.공시 • Feb 16Genus plc Provides Earnings Guidance for the First Half of Fiscal 2024Genus plc provided earnings guidance for the first half of fiscal 2024. For the first half period, management expects to report revenue of £334 Million.공시 • Dec 12Genus Appoints Ralph Heuser as Non-Executive Director, with effect from 1 January 2024Genus announced the appointment of Dr Ralph Heuser to the Board as a Non-Executive Director, with effect from 1 January 2024. Dr Heuser has had extensive experience in animal healthcare businesses globally, having worked at Pfizer, Boehringer Ingelheim, where he launched a PRRS vaccine in Germany, Novartis's Consumer and Animal Health divisions and more recentlyin global leadership roles at Elanco Animal Health, including as Vice President for Asia Pacific, Europe and International Commercial Operations. Dr Heuserhas a PhD in Agricultural Economics from the University of Bonn, Germany andis currently a Senior Advisor with Stonehaven Consulting (SC Group) AG. Dr Heuser brings widespread global experience in operations, commercial excellence, integration and the animal health industry generally, and his appointment follows an extensive search process using an external search agency.공시 • Nov 24+ 2 more updatesGenus plc to Report Fiscal Year 2024 Results on Sep 05, 2024Genus plc announced that they will report fiscal year 2024 results on Sep 05, 2024공시 • Nov 23Genus plc Approves to Declare Final DividendGenus plc at its AGM held on 22 November 2023, approved to declare a final dividend of 21.7 pence per Ordinary Share.공시 • Oct 08Colombian Government Gives Positive Determination for Genus's PRRS Virus-Resistant PigsGenus plc announced that the government of Colombia has given a favourable regulatory determination for Genus's Porcine Reproductive and Respiratory Syndrome virus ("PRRS") resistant pigs. This enables the future sale of such pigs in Colombia. PRRS is one of the most significant diseases in the pig industry, causing severe respiratory distress, increased secondary infections, pregnancy loss and increased morbidity and mortality. There are currently no effective vaccines or treatments. The creation of a PRRS resistant pig therefore represents a significant step forward in the welfare of pigs by protecting themthem from this devastating virus. It is estimated that PRRS costs the US and EU pig industry approximately $2 billion each year. Genus has used its gene editing platform to develop pigs resistant to PRRS, by deleting a very small portion of the pigs' DNA that encodes a protein that the virus uses to enter and infect the pigs' cells. With this small gene edit, the pig is resistant to PRRS, as the virus is unable to enter the cells and replicate. The Colombian government is the first to issue a determination for Genus's PRRS resistant pigs, enabling the future commercialisation of the pigs. The PRRS resistant pigs will be treated in the same way as any other pigs in Colombia. Further regulatory approvals for the PRRS resistant pig are also being sought in the United States, Canada, China, Japan, Mexico, Brazil and other countries. Genus anticipates a decision from the United States Food and Drug Administration in the first half of 2024, to be followed by a phased global launch of the pigs, subject to receiving applicable regulatory approvals. Genus will be hosting a Capital Markets Event in London on 1 November 2023 to provide additional information on its PRRS resistant pig development, registration and commercialisation programme.공시 • Aug 24Genus plc Announces Lykele Van Der Broek to Step Down from the Genus BoardGenus plc announces that Lykele van der Broek, Non-Executive Director, has informed the Company of his intention to step down from the Genus Board, effective from the conclusion of the 2023 Annual General Meeting on 22 November 2023, after nine years' service as a Non-Executive Director. Russell Reynolds has been retained and is in the process of identifying potential successors for Lykele.공시 • Aug 11AB Agri Ltd. completed the acquisition of National Milk Records plc (OFEX:NMRP) from Livestock Improvement Corporation Limited (NZSE:LIC), ICM Investment Management Limited, Genus plc (LSE:GNS), Custodial Capital Management Limited, High Street Partners, Ltd, and Working Capital Partners Ltd.AB Agri Ltd. made an offer to acquire National Milk Records plc (OFEX:NMRP) from Livestock Improvement Corporation Limited (NZSE:LIC), ICM Investment Management Limited, Genus plc (LSE:GNS), Custodial Capital Management Limited, High Street Partners, Ltd, and Working Capital Partners Ltd £45.7 million on June 6, 2023. The offer per share is £2.15. The cash consideration payable to the NMR Shareholders under the terms of the Acquisition will be financed by existing cash resources available to ABF. The Acquisition will be on the terms and subject to the Conditions including, among other things, the approval of Scheme Shareholders at the Court Meeting and the passing of the Resolutions to be proposed at the General Meeting, the CMA confirming in response to a briefing note that it has no further questions or, alternatively, CMA approval, he sanction of the Scheme by the Court; and the Scheme becoming Effective no later than the Long Stop Date. The Acquisition does not require the approval of ABF shareholders. The long stop date of the transaction is February 29, 2024. Stuart Vincent and Simon Cope-Thompson of N M Rothschild & Sons Limited as financial adviser to ABF, is satisfied that sufficient cash resources are available to ABF to enable it to satisfy in full the cash consideration payable to NMR Shareholders under the terms of the Acquisition. Addleshaw Goddard LLP is providing legal advice to ABF. Gowling WLG (UK) LLP is providing legal advice to NMR. Holly Gillis and Angharad Couch of Citigate Dewe Rogerson Ltd. acted as financial advisor to ABF. Megan Ray and Rachael Brooks of BlytheRay acted as financial advisor to NMR. Adam James and Harry Rees of Canaccord Genuity Limited acted as financial advisor to NMR. Equiniti Limited acted as a transfer agent to NMR. Canaccord Genuity Limited acted as fairness Opinion Provider to NMR. Ashurst LLP acted as legal advisor to N.M. Rothschild & Sons Limited in the transaction. AB Agri Ltd. completed the acquisition of National Milk Records plc (OFEX:NMRP) from Livestock Improvement Corporation Limited (NZSE:LIC), ICM Investment Management Limited, Genus plc (LSE:GNS), Custodial Capital Management Limited, High Street Partners, Ltd, and Working Capital Partners Ltd on August 9, 2023.공시 • Jun 07AB Agri Ltd. made an offer to acquire National Milk Records plc (OFEX:NMRP) from Livestock Improvement Corporation Limited (NZSE:LIC), ICM Investment Management Limited, Genus plc (LSE:GNS), Custodial Capital Management Limited, High Street Partners, Ltd, and Working Capital Partners Ltd £45.7 million.AB Agri Ltd. made an offer to acquire National Milk Records plc (OFEX:NMRP) from Livestock Improvement Corporation Limited (NZSE:LIC), ICM Investment Management Limited, Genus plc (LSE:GNS), Custodial Capital Management Limited, High Street Partners, Ltd, and Working Capital Partners Ltd £45.7 million on June 6, 2023. The offer per share is £2.15. The cash consideration payable to the NMR Shareholders under the terms of the Acquisition will be financed by existing cash resources available to ABF. The Acquisition will be on the terms and subject to the Conditions including, among other things, the approval of Scheme Shareholders at the Court Meeting and the passing of the Resolutions to be proposed at the General Meeting, the CMA confirming in response to a briefing note that it has no further questions or, alternatively, CMA approval, he sanction of the Scheme by the Court; and the Scheme becoming Effective no later than the Long Stop Date. The Acquisition does not require the approval of ABF shareholders. The long stop date of the transaction is February 29, 2024. Stuart Vincent and Simon Cope-Thompson of N M Rothschild & Sons Limited as financial adviser to ABF, is satisfied that sufficient cash resources are available to ABF to enable it to satisfy in full the cash consideration payable to NMR Shareholders under the terms of the Acquisition. Addleshaw Goddard LLP is providing legal advice to ABF. Gowling WLG (UK) LLP is providing legal advice to NMR. Holly Gillis and Angharad Couch of Citigate Dewe Rogerson Ltd. acted as financial advisor to ABF. Megan Ray and Rachael Brooks of BlytheRay acted as financial advisor to NMR. Adam James and Harry Rees of Canaccord Genuity Limited acted as financial advisor to NMR. Equiniti Limited acted as a transfer agent to NMR. Canaccord Genuity Limited acted as fairness Opinion Provider to NMR.공시 • Dec 07+ 2 more updatesGenus plc to Report Fiscal Year 2023 Results on Sep 07, 2023Genus plc announced that they will report fiscal year 2023 results on Sep 07, 2023이익 및 매출 성장 예측OTCPK:GENS.F - 애널리스트 향후 추정치 및 과거 재무 데이터 (GBP Millions)날짜매출이익자유현금흐름영업현금흐름평균 애널리스트 수6/30/2028705657210696/30/2027690586598126/30/202667712657781212/31/2025672484664N/A9/30/2025672334766N/A6/30/2025673194967N/A3/31/202567284058N/A12/31/2024672-43149N/A9/30/202467021840N/A6/30/20246698530N/A3/31/202467121837N/A12/31/2023673331045N/A9/30/2023681331348N/A6/30/2023690331550N/A3/31/202367634-142N/A12/31/202266234-1835N/A9/30/202262838-2534N/A6/30/202259341-3134N/A3/31/202258239-2039N/A12/31/202157037-943N/A9/30/2021572421355N/A6/30/2021574473468N/A3/31/2021570454270N/A12/31/2020566425072N/A9/30/2020559394066N/A6/30/2020551353060N/A3/31/2020536372555N/A12/31/2019520391949N/A9/30/201950423N/A41N/A6/30/20194898N/A33N/A3/31/20194801N/A35N/A12/31/2018471-7N/A37N/A9/30/201847018N/A40N/A6/30/201847043N/A43N/A3/31/201847355N/A42N/A12/31/201747667N/A41N/A9/30/201746750N/A38N/A6/30/201745933N/A35N/A3/31/201744140N/A34N/A12/31/201642247N/A33N/A9/30/201640548N/A31N/A6/30/201638849N/A30N/A3/31/201638840N/A25N/A12/31/201538831N/A21N/A9/30/201539335N/A28N/A6/30/201539940N/A35N/A더 보기애널리스트 향후 성장 전망수입 대 저축률: GENS.F 의 수익은 향후 3년간 감소할 것으로 예상됩니다(연간 -2.7%).수익 vs 시장: GENS.F 의 수익은 향후 3년간 감소할 것으로 예상됩니다(연간 -2.7%).고성장 수익: GENS.F 의 수익은 향후 3년간 감소할 것으로 예상됩니다.수익 대 시장: GENS.F 의 수익(연간 3.2%)이 US 시장(연간 11.7%)보다 느리게 성장할 것으로 예상됩니다.고성장 매출: GENS.F 의 수익(연간 3.2%)은 연간 20%보다 느리게 증가할 것으로 예상됩니다.주당순이익 성장 예측향후 자기자본이익률미래 ROE: GENS.F의 자본 수익률은 3년 후 10.4%로 낮을 것으로 예상됩니다.성장 기업 찾아보기7D1Y7D1Y7D1YPharmaceuticals-biotech 산업의 고성장 기업.View Past Performance기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2026/05/17 06:27종가2026/05/13 00:00수익2025/12/31연간 수익2025/06/30데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스Genus plc는 18명의 분석가가 다루고 있습니다. 이 중 12명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.분석가기관Robert ChantryBerenbergMatthew LloydBNP ParibasAlexander JonesBofA Global Research15명의 분석가 더 보기
공시 • Feb 16Genus plc Provides Earnings Guidance for the First Half of Fiscal 2024Genus plc provided earnings guidance for the first half of fiscal 2024. For the first half period, management expects to report revenue of £334 Million.
공시 • Jan 24+ 1 more updateHealth Canada and CFIA Announce Completion of Safety Assessments on PRRSV-Resistant Pigs from Genus PLC and PIC Canada, LtdHealth Canada and the Canadian Food Inspection Agency (CFIA) announced the completion of independent, comprehensive safety assessments on pigs resistant to PRRSV following applications from Genus PLC and PIC Canada Ltd., respectively. Health Canada has concluded that foods made from these pigs are as safe and nutritious for people to eat as pork currently available in Canada. The CFIA has confirmed that these pigs are also safe and effective for use in livestock feeds. Improving resistance to PRRSV in pigs will help farmers avoid illness in their herds from these viruses, reduce antibiotic use, and improve animal welfare, while supporting a more stable, affordable and sustainable food supply. Genus PLC's PRRSV-resistant pigs are already permitted for food use in the U.S., Brazil, Colombia and the Dominican Republic. Genus PLC has indicated that even though Canada has approved the sale of PRRSV resistant pigs, the company does not intend to sell these pigs before further regulatory authorization in other key markets. The company and Health Canada are committed to the highest level of transparency and will communicate to the public when this new technology enters the Canadian market. While genetically engineered foods are considered as safe and nutritious as conventional foods, the Government of Canada recognizes that information about genetic engineering is important. That is why have been working with the Canadian General Standards Board since November on a public review of the National Standard for labelling and advertising of foods that are, and are not, products of genetic engineering. The CFIA uses this Standard to provide its guidance to companies on the labelling of foods.
공시 • Jan 08Genus plc to Report Fiscal Year 2026 Results on Sep 10, 2026Genus plc announced that they will report fiscal year 2026 results on Sep 10, 2026
공시 • Nov 21+ 1 more updateGenus plc Approves to Appoint Andrew Russell as A DirectorGenus plc announced that at its AGM held on 19 November 2025, the shareholder approved to elect Andrew Russell as a Director of the Company.
공시 • Nov 20Genus plc Announces Board AppointmentsGenus plc announced the appointment of Dr Celia Baxter to the Board as a Non-Executive Director with effect from 19 November 2025, and the appointment of Dr Robert Reiter as a Non-Executive Director with effect from 1 January 2026. Dr Baxter has had extensive experience inpeople-driven, multisite, manufacturing, services and distribution businesses across business sectors in international FTSE 100 and FTSE 250 companies as well as Big Four consulting, having worked in increasingly senior Human Resources roles at Ford Motor Company, KPMG, Sherwood Computer Services, Tate & Lyle, Enterprise Oil plc, Hays and Bunzl where she was Group Human Resources Director. Dr Baxter has a PhD in Botany from Reading Universityandis currently a non-executive director and remuneration committee chair of Volution Group plc, senior independent director and remuneration committee chair of discoverIE Group plc, and senior independent director and remuneration committee chair of Dowlais Group plc. She was previously a non-executive director of Senior plc, RHI Magnesita NV and Bekaert SA. Dr Baxter brings widespread global experience in Human Resources, Strategy, Branding, Mergers and Acquisitions and Change Management. Dr Reiteris a plant geneticist by training and spent his executive career delivering innovative new technologies and products within crop agriculture, having worked in E.I. DuPont de Nemours, followed by twenty years in increasingly senior scientific and supply chain leadership roles at Monsanto. Bob was the R&D Integration Planning Lead for the Bayer-Monsanto merger, collaborating with Bayer to design a world-class agricultural R&D organisation, overseeing an annual investment portfolio exceeding $2.3 billion. Following the acquisition of Monsanto, Bob became an Executive Vice President leading Research & Development for the combined Bayer Crop Science division, and integrated the two divisions with accountability of over 7,000 employees.
공시 • Nov 19Genus plc to Report First Half, 2026 Results on Feb 26, 2026Genus plc announced that they will report first half, 2026 results on Feb 26, 2026
공시 • Oct 10Genus plc, Annual General Meeting, Nov 19, 2025Genus plc, Annual General Meeting, Nov 19, 2025. Location: buchanan communications, 107 cheapside, ec2v 6dn, london United Kingdom
공시 • Sep 04Genus plc Proposes Final Dividend for the Year 2025, Payable on December 5, 2025Genus plc proposed a final dividend of 21.7 pence per share for 2025. This is subject to shareholders' approval at the AGM and we have therefore not included it as a liability in these Financial Statements. The total proposed and paid dividend for year ended 30 June 2025 is 32.0 pence per share (2024: 32.0 pence per share). It is proposed that the final dividend will be paid on 5 December 2025 to the shareholders on the register at the close of business on 7 November 2025.
공시 • May 02Genus plc Announces the Update in Relation to Its Innovative Prrs 1 Resistant Pig ProgrammeGenus announced that the U.S. Food and Drug Administration ("FDA") has approved the PRP gene edit for use in the U.S. food supply chain, in line with expectations. This landmark approval follows years of close collaboration with the FDA and is a significant step on the pathway to PRP commercialisation in the U.S. Genus believes successful U.S. commercialisation also requires approvals in key U.S. export markets, being Mexico, Canada and Japan. The Group continues to make progress with regulators in these jurisdictions as well as with other international regulators, including China. Brazil, Colombia and, more recently, the Dominican Republic have already issued positive determinations for PRP, meaning those countries will regulate the PRP the same as any other pigs. PRRS is one of the most devastating global pig diseases and causes suffering and premature death for pigs. Recent research indicates that PRRS also increases the need for antibiotics by more than 200%.
공시 • Mar 13+ 1 more updateGenus plc Appoints Andy Russell as Chief Financial Officer, Effective August 1, 2025The Board of Genus plc announced that it has appointed Andy Russell as Chief Financial Officer. Andy will commence with Genus and join the Board on 1 August 2025, taking over from Alison Henriksen after she retires from the Company on 31 July 2025, after more than five years in the role. Andy is an experienced CFO, who will join Genus after nearly 12 years with global medical device manufacturer Smith & Nephew plc. He currently serves as Senior Vice President, Group Finance and M&A, operating as deputy to the Group CFO and leading approximately 400 people globally as he oversaw Group reporting, Controllership, FP&A, Tax, Treasury and M&A. This follows a succession of increasingly senior roles within the organisation, including CFO for the Global Orthopedics division, Interim President for EMEA and CFO for EMEA (while also acting as Finance lead for Global M&A and Strategic Projects). Before joining Smith & Nephew, Andy spent 17 years with KPMG, the last three of them as a Director, Transaction Services in the National Markets Division and the Private Equity Group.
공시 • Feb 26Genus plc Announces Retirement of Jason Chin as Non-Executive Director from the Board, Effective from the End of May 2025Genus plc announced that Professor Jason Chinhas informed the Company of his intention to step down from the Genus Board, effective from the end of May 2025, as he will be taking on a significant new role as Founding Director of the Generative Biology Institute at the Ellison Institute of Technology. Professor Chin has served as a Non-Executive Director, Chairman of the Company's Scientific Advisory Board and advisor to the Company's Global Portfolio Steering Committee for four years. Upon stepping down from the Board, Professor Chin will remain a member of the Scientific Advisory Board. The Board has initiated a comprehensive search for Professor Chin's successor and will provide an update once this process has concluded.
공시 • Nov 30Genus plc to Report Fiscal Year 2025 Results on Sep 04, 2025Genus plc announced that they will report fiscal year 2025 results on Sep 04, 2025
공시 • Nov 21Genus plc Declares A Final DividendGenus plc declared a final dividend of 21.7 pence per Ordinary Share, at its AGM held on 20 November 2024.
공시 • Nov 20Genus plc to Report First Half, 2025 Results on Feb 27, 2025Genus plc announced that they will report first half, 2025 results on Feb 27, 2025
공시 • Oct 22Genus plc Announces Retirement of Alison Henriksen as Chief Financial Officer, Until 31 July 2025Genus announced that Alison Henriksen, Chief Financial Officer, has informed the Board of her intention to retire after five years with the Group. Alison will remain in her existing role until 31 July 2025 to assist with the transition and continue to focus on delivery of the Group's strategic priorities until her retirement.
공시 • Sep 05Genus plc Proposes Final Dividend for the Year Ended June 30, 2024, Payable on 6 December 2024Genus plc board proposed a final dividend of 21.7 pence per ordinary share, consistent with the prior year final dividend. Payable on, 6 December 2024 to the shareholders on the register at the close of business on 8 November 2024.
공시 • Feb 16Genus plc Provides Earnings Guidance for the First Half of Fiscal 2024Genus plc provided earnings guidance for the first half of fiscal 2024. For the first half period, management expects to report revenue of £334 Million.
공시 • Dec 12Genus Appoints Ralph Heuser as Non-Executive Director, with effect from 1 January 2024Genus announced the appointment of Dr Ralph Heuser to the Board as a Non-Executive Director, with effect from 1 January 2024. Dr Heuser has had extensive experience in animal healthcare businesses globally, having worked at Pfizer, Boehringer Ingelheim, where he launched a PRRS vaccine in Germany, Novartis's Consumer and Animal Health divisions and more recentlyin global leadership roles at Elanco Animal Health, including as Vice President for Asia Pacific, Europe and International Commercial Operations. Dr Heuserhas a PhD in Agricultural Economics from the University of Bonn, Germany andis currently a Senior Advisor with Stonehaven Consulting (SC Group) AG. Dr Heuser brings widespread global experience in operations, commercial excellence, integration and the animal health industry generally, and his appointment follows an extensive search process using an external search agency.
공시 • Nov 24+ 2 more updatesGenus plc to Report Fiscal Year 2024 Results on Sep 05, 2024Genus plc announced that they will report fiscal year 2024 results on Sep 05, 2024
공시 • Nov 23Genus plc Approves to Declare Final DividendGenus plc at its AGM held on 22 November 2023, approved to declare a final dividend of 21.7 pence per Ordinary Share.
공시 • Oct 08Colombian Government Gives Positive Determination for Genus's PRRS Virus-Resistant PigsGenus plc announced that the government of Colombia has given a favourable regulatory determination for Genus's Porcine Reproductive and Respiratory Syndrome virus ("PRRS") resistant pigs. This enables the future sale of such pigs in Colombia. PRRS is one of the most significant diseases in the pig industry, causing severe respiratory distress, increased secondary infections, pregnancy loss and increased morbidity and mortality. There are currently no effective vaccines or treatments. The creation of a PRRS resistant pig therefore represents a significant step forward in the welfare of pigs by protecting themthem from this devastating virus. It is estimated that PRRS costs the US and EU pig industry approximately $2 billion each year. Genus has used its gene editing platform to develop pigs resistant to PRRS, by deleting a very small portion of the pigs' DNA that encodes a protein that the virus uses to enter and infect the pigs' cells. With this small gene edit, the pig is resistant to PRRS, as the virus is unable to enter the cells and replicate. The Colombian government is the first to issue a determination for Genus's PRRS resistant pigs, enabling the future commercialisation of the pigs. The PRRS resistant pigs will be treated in the same way as any other pigs in Colombia. Further regulatory approvals for the PRRS resistant pig are also being sought in the United States, Canada, China, Japan, Mexico, Brazil and other countries. Genus anticipates a decision from the United States Food and Drug Administration in the first half of 2024, to be followed by a phased global launch of the pigs, subject to receiving applicable regulatory approvals. Genus will be hosting a Capital Markets Event in London on 1 November 2023 to provide additional information on its PRRS resistant pig development, registration and commercialisation programme.
공시 • Aug 24Genus plc Announces Lykele Van Der Broek to Step Down from the Genus BoardGenus plc announces that Lykele van der Broek, Non-Executive Director, has informed the Company of his intention to step down from the Genus Board, effective from the conclusion of the 2023 Annual General Meeting on 22 November 2023, after nine years' service as a Non-Executive Director. Russell Reynolds has been retained and is in the process of identifying potential successors for Lykele.
공시 • Aug 11AB Agri Ltd. completed the acquisition of National Milk Records plc (OFEX:NMRP) from Livestock Improvement Corporation Limited (NZSE:LIC), ICM Investment Management Limited, Genus plc (LSE:GNS), Custodial Capital Management Limited, High Street Partners, Ltd, and Working Capital Partners Ltd.AB Agri Ltd. made an offer to acquire National Milk Records plc (OFEX:NMRP) from Livestock Improvement Corporation Limited (NZSE:LIC), ICM Investment Management Limited, Genus plc (LSE:GNS), Custodial Capital Management Limited, High Street Partners, Ltd, and Working Capital Partners Ltd £45.7 million on June 6, 2023. The offer per share is £2.15. The cash consideration payable to the NMR Shareholders under the terms of the Acquisition will be financed by existing cash resources available to ABF. The Acquisition will be on the terms and subject to the Conditions including, among other things, the approval of Scheme Shareholders at the Court Meeting and the passing of the Resolutions to be proposed at the General Meeting, the CMA confirming in response to a briefing note that it has no further questions or, alternatively, CMA approval, he sanction of the Scheme by the Court; and the Scheme becoming Effective no later than the Long Stop Date. The Acquisition does not require the approval of ABF shareholders. The long stop date of the transaction is February 29, 2024. Stuart Vincent and Simon Cope-Thompson of N M Rothschild & Sons Limited as financial adviser to ABF, is satisfied that sufficient cash resources are available to ABF to enable it to satisfy in full the cash consideration payable to NMR Shareholders under the terms of the Acquisition. Addleshaw Goddard LLP is providing legal advice to ABF. Gowling WLG (UK) LLP is providing legal advice to NMR. Holly Gillis and Angharad Couch of Citigate Dewe Rogerson Ltd. acted as financial advisor to ABF. Megan Ray and Rachael Brooks of BlytheRay acted as financial advisor to NMR. Adam James and Harry Rees of Canaccord Genuity Limited acted as financial advisor to NMR. Equiniti Limited acted as a transfer agent to NMR. Canaccord Genuity Limited acted as fairness Opinion Provider to NMR. Ashurst LLP acted as legal advisor to N.M. Rothschild & Sons Limited in the transaction. AB Agri Ltd. completed the acquisition of National Milk Records plc (OFEX:NMRP) from Livestock Improvement Corporation Limited (NZSE:LIC), ICM Investment Management Limited, Genus plc (LSE:GNS), Custodial Capital Management Limited, High Street Partners, Ltd, and Working Capital Partners Ltd on August 9, 2023.
공시 • Jun 07AB Agri Ltd. made an offer to acquire National Milk Records plc (OFEX:NMRP) from Livestock Improvement Corporation Limited (NZSE:LIC), ICM Investment Management Limited, Genus plc (LSE:GNS), Custodial Capital Management Limited, High Street Partners, Ltd, and Working Capital Partners Ltd £45.7 million.AB Agri Ltd. made an offer to acquire National Milk Records plc (OFEX:NMRP) from Livestock Improvement Corporation Limited (NZSE:LIC), ICM Investment Management Limited, Genus plc (LSE:GNS), Custodial Capital Management Limited, High Street Partners, Ltd, and Working Capital Partners Ltd £45.7 million on June 6, 2023. The offer per share is £2.15. The cash consideration payable to the NMR Shareholders under the terms of the Acquisition will be financed by existing cash resources available to ABF. The Acquisition will be on the terms and subject to the Conditions including, among other things, the approval of Scheme Shareholders at the Court Meeting and the passing of the Resolutions to be proposed at the General Meeting, the CMA confirming in response to a briefing note that it has no further questions or, alternatively, CMA approval, he sanction of the Scheme by the Court; and the Scheme becoming Effective no later than the Long Stop Date. The Acquisition does not require the approval of ABF shareholders. The long stop date of the transaction is February 29, 2024. Stuart Vincent and Simon Cope-Thompson of N M Rothschild & Sons Limited as financial adviser to ABF, is satisfied that sufficient cash resources are available to ABF to enable it to satisfy in full the cash consideration payable to NMR Shareholders under the terms of the Acquisition. Addleshaw Goddard LLP is providing legal advice to ABF. Gowling WLG (UK) LLP is providing legal advice to NMR. Holly Gillis and Angharad Couch of Citigate Dewe Rogerson Ltd. acted as financial advisor to ABF. Megan Ray and Rachael Brooks of BlytheRay acted as financial advisor to NMR. Adam James and Harry Rees of Canaccord Genuity Limited acted as financial advisor to NMR. Equiniti Limited acted as a transfer agent to NMR. Canaccord Genuity Limited acted as fairness Opinion Provider to NMR.
공시 • Dec 07+ 2 more updatesGenus plc to Report Fiscal Year 2023 Results on Sep 07, 2023Genus plc announced that they will report fiscal year 2023 results on Sep 07, 2023